NKT3964, a novel oral CDK2 degrader developed by NiKang Therapeutics, is currently in a Phase 1 clinical trial targeting advanced or metastatic solid tumors. The trial's dual-phase design includes a dose escalation phase to establish a recommended dose for expansion (RDE) and an expansion phase to evaluate preliminary anti-tumor activity. The focus on specific tumor types with CCNE1 amplification, particularly in breast and ovarian cancers, positions NKT3964 in a niche market with unmet needs. Given the increasing interest in targeted therapies and protein degraders, NKT3964 could capture significant market share if it demonstrates efficacy and safety, especially in patients refractory to existing therapies. Competitive analysis indicates that while several CDK inhibitors are available, the unique mechanism of action as a degrader may provide a differentiated therapeutic profile. Diligence should focus on regulatory pathways and potential partnerships for commercialization.